![Stephen Brannan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stephen Brannan
No open positions remaining
Net worth: 24 533 $ as of 30/05/2026
Profile
Stephen Brannan is Director at Serina Therapeutics, Inc. since 2025.
Dr. Brannan is a Member of the International Society for CNS Drug Development, American College of Neuropsychopharmacology, International Society For CNS Clinical Trials & Methodology, Alan Aragon's Research Review, and CNS Summit.
Former roles include Chief Medical Officer at Karuna Therapeutics, Inc. from 2017 to 2024, Vice President-Clinical Research & Medical Affairs at FORUM Pharmaceuticals, Inc. from 2015 to 2016, and Head-Neuroscience at Takeda Pharmaceutical Co., Ltd. from 2011 to 2015.
Education includes a doctorate from The University of Texas Southwestern Medical Center and an undergraduate degree from Harvard College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.09% | 16/06/2026 | 13,333 ( 0.09% ) | 24 533 $ | 30/05/2026 |
Stephen Brannan active positions
| Companies | Position | Start |
|---|---|---|
American College of Neuropsychopharmacology
 American College of Neuropsychopharmacology Miscellaneous Commercial ServicesCommercial Services Operates as a neuron psychopharmacology school | Corporate Officer/Principal | - |
International Society for CNS Drug Development
 International Society for CNS Drug Development Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. It promotes collaboration among academia, industry, and government to address scientific challenges in CNS drug development. ISCDD provides resources such as the GRID-Hamilton Depression Rating Scale (GRID-HAMD), which separately rates symptom intensity and frequency, and the Medication Satisfaction Questionnaire (MSQ), both available for licensing and adaptable to various languages and settings. The organization also offers the Uncorrelated PANSS Score Matrix (UPSM™), an analytical tool for refining the assessment of schizophrenia symptoms. The society facilitates knowledge sharing through annual meetings. The International Society for CNS Drug Development (ISCDD) is a non-profit, independent organization founded in 2002 to advance methodologies in central nervous system (CNS) research. | Corporate Officer/Principal | - |
International Society For Cns Clinical Trials & Methodology | Corporate Officer/Principal | - |
Alan Aragon's Research Review | Corporate Officer/Principal | - |
Cns Summit
 Cns Summit Miscellaneous Commercial ServicesCommercial Services Provides advanced clinical development services | Corporate Officer/Principal | - |
Former positions of Stephen Brannan
| Companies | Position | End |
|---|---|---|
| KARA THER | Chief Tech/Sci/R&D Officer | 17/03/2024 |
FORUM Pharmaceuticals, Inc.
 FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for central nervous system disorders | Chief Tech/Sci/R&D Officer | 31/05/2016 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 31/07/2015 |
Training of Stephen Brannan
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
32
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for central nervous system disorders | Health Technology |
Takeda Pharmaceutical Co., Ltd.
 Takeda Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, manufacturing and marketing of pharmaceutical products | Health Technology |
International Society for CNS Drug Development
International Society for CNS Drug Development Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. It promotes collaboration among academia, industry, and government to address scientific challenges in CNS drug development. ISCDD provides resources such as the GRID-Hamilton Depression Rating Scale (GRID-HAMD), which separately rates symptom intensity and frequency, and the Medication Satisfaction Questionnaire (MSQ), both available for licensing and adaptable to various languages and settings. The organization also offers the Uncorrelated PANSS Score Matrix (UPSM™), an analytical tool for refining the assessment of schizophrenia symptoms. The society facilitates knowledge sharing through annual meetings. The International Society for CNS Drug Development (ISCDD) is a non-profit, independent organization founded in 2002 to advance methodologies in central nervous system (CNS) research. | Commercial Services |
The University of Texas Southwestern Medical Center
 The University of Texas Southwestern Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicines for psychiatric and neurological disorders like schizophrenia and Alzheimer’s disease | Health Technology |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology Miscellaneous Commercial ServicesCommercial Services Operates as a neuron psychopharmacology school | Commercial Services |
International Society For Cns Clinical Trials & Methodology | |
Alan Aragon's Research Review | |
Cns Summit
Cns Summit Miscellaneous Commercial ServicesCommercial Services Provides advanced clinical development services | Commercial Services |
- Stock Market
- Insiders
- Stephen Brannan
Choose MarketScreener 
